A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute

About this trial

This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in reducing the complexity of both laparoscopic lymphadenectomy and/or organ removal in patients with a confirmed diagnosis of cancer in urologic regions of interest (Bladder, Prostate, Testicular, Kidney, Urethral, and Penis), by resulting in better visualization and more accurate localization of certain areas in the diseased organ or the diseased lymph node, and allowing for improved surgical and patient outcomes, fewer complications and better clinician performance.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management

Subjects aged ≥ 18 years. Selected patients must have a confirmed or suspected diagnosis of disease in urologic regions of interest, with scheduled confirmatory surgical biopsy.

Subjects must have had either of the following scans: CT, PET or MR of acceptable quality at Brigham and Women's Hospital within the past year.

Subjects must also be scheduled to undergo lymph node dissection for a urologic cancer or organ removal of any of the following urologic regions of interest: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum

Disqualifiers

Severely impaired renal function with an EGFR < 30 mL/min/body surface area

Evidence of any significant, uncontrolled comorbid condition that could affect compliance with the protocol or interpretation of the results, which is to be judged at the discretion of the PI

History of hypersensitivity or other contraindication to contrast media

Contraindication to general anesthesia

Trial design

Design model

Single group

Treatments tested in this trial

  • Electromagnetic Guided Laparoscopy

    Device

    Standard Care

  • Ultrasound

    Device

    Standard Care

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Electromagnetic Guided Laparoscopy + UltrasoundExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Laparoscope Images

Laparoscope images are images recorded by the laparoscope surgical device.

Time frame
1 year
2

Ultrasound Images

Ultrasound Images are images taken by an ultrasound probe.

Time frame
1 year
3

Electromagnetic Tracking Data

Electromagnetic tracking data is gathered from the movements made by the laparoscope surgical device during surgery. First-order statistics measures will be computed, which include Kinematics metrics such as laparoscope path length, velocity, acceleration, and jerk. We will analyze the data using a mixed model regression analysis with kinematics metrics as the response and subject as the random effect. Since the kinematics measures are time series, we will address the temporal correlation in this regression model. The fixed effects in this model will include target tissue type, CT Hansfield units, surgeon assessment of navigation difficulty, and patient's BMI. We will test for kinematics outliers by applying the Grubb's test. If there are kinematics outliers, we will try to explain them by going back to the scan and patient history.

Time frame
1 year

Secondary outcomes

1

Retrospective navigation accuracy

We are collecting data for future assessment of navigation systems, in those studies the primary out will be navigation accuracy We will analyze the data using a mixed model regression analysis with navigation accuracy as the response and subject as the random effect, as above. We will test for accuracy outliers by applying the Grubb's test and investigate accuracy outliers.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dana-Farber Cancer Institute

Lead sponsor

Brigham and Women's Hospital

Sponsor institution

Siemens Medical Solutions

Collaborator